Literature DB >> 23824073

Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.

Shiguo Liu1, Yue Fang, Huiling Shen, Wenlin Xu, Hao Li.   

Abstract

Recent studies have shown that microRNA-21 (miR-21) contributes to tumor resistance to chemotherapy. Interestingly, we have found that berberine could inhibit miR-21 expression in several cancer cell lines. In this study, we investigated whether berberine could modulate the sensitivity of ovarian cancer cells to cisplatin and explored the mechanism. The cisplatin-resistant SKOV3 cells that were incubated with berberine combined with cisplatin had a significantly lower survival than the cisplatin alone group and enhanced cisplatin-induced apoptosis. Berberine could inhibit miR-21 expression and function in ovarian cancer, as shown by an enhancement of its target PDCD4, an important tumor suppressor in ovarian cancer. The results suggested that berberine could modulate the sensitivity of cisplatin via regulating miR-21/PDCD4 axis in the ovarian cancer cells.

Entities:  

Keywords:  berberine; miR-21; ovarian cancer

Mesh:

Substances:

Year:  2013        PMID: 23824073     DOI: 10.1093/abbs/gmt075

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  23 in total

1.  Berberine regulates the microRNA-21-ITGΒ4-PDCD4 axis and inhibits colon cancer viability.

Authors:  Yanfeng Lü; Bingbing Han; Hualong Yu; Zhenghua Cui; Zhiwen Li; Jianxin Wang
Journal:  Oncol Lett       Date:  2018-02-08       Impact factor: 2.967

2.  [Role of miR-206/CDK4 in modulating the growth and chemotlerapy sensitivity of ovarian cancer cells].

Authors:  Chen Ling; Shu Liu; Yong Wang; Feng-Chun Zhang; Ying DU
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-03-20

3.  The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.

Authors:  Zhen Chen; Karin A Vallega; Haiying Chen; Jia Zhou; Suresh S Ramalingam; Shi-Yong Sun
Journal:  Pharmacol Res       Date:  2021-11-24       Impact factor: 7.658

4.  Circulating miR-21 as an independent predictive biomarker for chemoresistance in esophageal squamous cell carcinoma.

Authors:  Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Taisuke Imamura; Jun Kiuchi; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Kazuma Okamoto; Eigo Otsuji
Journal:  Am J Cancer Res       Date:  2016-07-01       Impact factor: 6.166

5.  Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203.

Authors:  He-Yi You; Xue-Meng Xie; Wei-Jian Zhang; Heng-Liang Zhu; Fei-Zhao Jiang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-05-03       Impact factor: 2.416

Review 6.  Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.

Authors:  Mingo M H Yung; Hextan Y S Ngan; David W Chan
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-01-12       Impact factor: 3.848

7.  Prognostic value of miR-21 in various cancers: an updating meta-analysis.

Authors:  Xin Zhou; Xiaping Wang; Zebo Huang; Jian Wang; Wei Zhu; Yongqian Shu; Ping Liu
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

8.  Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells.

Authors:  Wenying Huo; Guannan Zhao; Jinggang Yin; Xuan Ouyang; Yinan Wang; Chuanhe Yang; Baojing Wang; Peixin Dong; Zhixiang Wang; Hidemichi Watari; Edward Chaum; Lawrence M Pfeffer; Junming Yue
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

Review 9.  MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy.

Authors:  Ming Hong; Ning Wang; Hor Yue Tan; Sai-Wah Tsao; Yibin Feng
Journal:  Cancers (Basel)       Date:  2015-08-24       Impact factor: 6.639

10.  Berberine-targeted miR-21 chemosensitizes oral carcinomas stem cells.

Authors:  Pei-Ling Hsieh; Yi-Wen Liao; Che-Yi Lin; Chih-Yu Peng; Ming-Yi Lu; Ching-Hsuan Yang; Cheng-Chia Yu; Chia-Ming Liu
Journal:  Oncotarget       Date:  2017-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.